RxDoctor Payments Data

Anthony Tickner

Primary Podiatric Medicine · Hudson, MANPI 1790872497

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (33.2%), other and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Convatec Inc. at 42.9% of the total. Reporting peaked in 2024 at $104,711 and has fallen 88.0% since, to $12,517 in 2025.

$283,938in general payments, 2019–2025

Across 214 payments — averaging $1326.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$122K
  • Kerecis Limited$86K
  • Integra Lifesciences Corporation$50K
  • Triad Life Sciences Inc.$9K
  • Urgo Medical North America, LLC$7K
  • Musculoskeletal Transplant Foundation Inc.$5K
  • plus $4K from 15 others

What the payments were for

  • Consulting fees$94,26533%
  • Speaking & faculty fees$74,78126%
  • Travel & lodging$20,4677%
  • Food & beverage$9,2893%
  • Education$3,9001%
  • Gifts$360%
  • Other$81,20029%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few primary podiatric medicine providers in Massachusettsto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$445,509
Medicare patients
747
Services billed
5,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip23$1,211
Cephalexin32$301
Ciprofloxacin Hcl59$275
Doxycycline Hyclate36$238
Clindamycin Hcl26$173
Mupirocin21$116

Paid to pharmacies, not to this prescriber.

Other primary podiatric medicine in Hudson

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →